Overcoming Hurdles in Rare Disease Therapy with Reenie McCarthy
In this episode of Clinical Trialblazers, host Alberto Grignolo sits down with Reenie McCarthy the CEO of Mighty Therapeutics, formerly known as Stealth Biotherapeutics. Reenie shares her path from venture investor to biotech CEO and discusses the scientific, regulatory, and funding challenges of developing a first-in-class therapy. She reflects on the role of patient advocacy, lessons in leadership and resilience, and how setbacks ultimately helped shape the company's success.
The conversation also explores the future of mitochondrial medicine and Mighty Therapeutics' mission to bring innovative treatments to patients with serious unmet needs.
Related Insights
CTB Podcast
Leading Neuroscience Innovation: A Biotech CEO Playbook with Neil Warma
Oct 5, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Podcast
Biotech’s Next Era: Data, AI and the Future of Decision-Making with Jay Roberts
Aug 28, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
CTB Webinar
Rethinking Phase I: Five strategies for faster proof of concept
Aug 4, 2026
CTB Podcast
A Journey through Academia, Big Pharma and Biotech: Building Breakthrough Medicines with Dr. Briggs Morrison
Aug 3, 2026
CTB Blog
Leveraging early-phase ethnobridging to reduce drug lag in China and Japan
Jul 15, 2026
CTB Blog
Modeling & simulation and artificial intelligence for early drug development
Jul 14, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
CTB Blog
In early phase trials, operations is where speed is won or lost
Jun 28, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
Related Insights
CTB Podcast
Leading Neuroscience Innovation: A Biotech CEO Playbook with Neil Warma
Oct 5, 2026
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Podcast
Biotech’s Next Era: Data, AI and the Future of Decision-Making with Jay Roberts
Aug 28, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
CTB Webinar
Rethinking Phase I: Five strategies for faster proof of concept
Aug 4, 2026
CTB Podcast
A Journey through Academia, Big Pharma and Biotech: Building Breakthrough Medicines with Dr. Briggs Morrison
Aug 3, 2026
CTB Blog
Leveraging early-phase ethnobridging to reduce drug lag in China and Japan
Jul 15, 2026
CTB Blog
Modeling & simulation and artificial intelligence for early drug development
Jul 14, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
CTB Blog
In early phase trials, operations is where speed is won or lost
Jun 28, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026